<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01914926</url>
  </required_header>
  <id_info>
    <org_study_id>09/01/VA02</org_study_id>
    <nct_id>NCT01914926</nct_id>
  </id_info>
  <brief_title>Comparison of Diltiazem and Metoprolol in the Management of Acute Atrial Fibrillation or Atrial Flutter</brief_title>
  <acronym>DiME</acronym>
  <official_title>DiME Study: Comparison of Diltiazem and Metoprolol in the Management of Acute Atrial Fibrillation or Atrial Flutter With Rapid Ventricular Response: A Prospective Randomized and Double-Blinded Non-Inferiority Trial of Safety and Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antonios Likourezos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute atrial fibrillation is the most common sustained, clinically significant dysrhythmia
      encountered in the emergency department (ED) and the most common dysrhythmia treated by
      emergency physicians. Atrial flutter is less common than atrial fibrillation but its
      management in the ED is very similar, and the majority of patients with atrial flutter also
      have atrial fibrillation. Symptomatic relief and ventricular rate control are generally the
      primary therapeutic objectives in the ED management of acute atrial fibrillation and flutter
      (AFF). The need for swift, appropriate action by the emergency physician is highlighted by
      the fact that up to 18% of patients with AFF develop potentially life-threatening
      complications such as congestive heart failure, hypotension, ventricular ectopy, respiratory
      failure, angina and myocardial infarction.

      Both beta-blocking agents and calcium channel blockers are commonly used to treat AFF in the
      ED. Metoprolol is the most commonly used beta-blocker; and diltiazem is the most frequently
      used calcium channel antagonist.[8] Diltiazem was released by the FDA for treatment of AFF in
      1992. Shreck et al. were the first to demonstrate both the efficacy of diltiazem in the ED
      management of AFF with rapid rate and its clear superiority over the previously most commonly
      used pharmacologic agent, digoxin.

      To date, only one prospective, randomized trial has compared the effectiveness of a calcium
      channel blocker (diltiazem) with a beta-blocker (metoprolol) for rate control of AFF in the
      ED. Despite the relatively small sample size (n=20 in each group) the authors concluded that
      both pharmacologic agents were similarly effective. In order to test this finding, the
      investigators conducted a prospective comparison of metoprolol and diltiazem for the
      management of patients presenting to the ED with AFF with rapid ventricular rate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We conducted a prospective, randomized, double-blind study to compare the effectiveness of
      intravenous metoprolol with that of diltiazem in achieving rate control in adult ED patients
      with rapid atrial fibrillation or flutter. Approval of the study was obtained from our
      hospital's institutional review board. All enrolled patients provided written informed
      consent and HIPAA authorization documentation.

      This study was set in the adult ED of Maimonides Medical Center, an urban teaching hospital
      in Brooklyn, NY with an annual ED census of more than 120,00 patients. A convenience sample
      of adult patients age 18 or older presenting with a supraventricular tachydysrhythmia were
      evaluated for enrollment. Eligible patients had to have a 12-lead electrocardiogram (ECG)
      showing atrial fibrillation or atrial flutter with a ventricular rate of greater than or
      equal to 120 beats per minute. Data collected included demographics, medical history, vital
      signs and electrocardiogram findings. All patients were immediately evaluated by the treating
      physician utilizing ACLS protocols. At the discretion of the treating physician, intravenous
      adenosine was administered in order to facilitate identification of the underlying
      supraventricular tachydysrhythmia. All patients were attached to a monitor that displays
      cardiac rhythm, heart rate, blood pressure and oxygen saturation.

      Upon enrollment, patients were randomly assigned, in a 1:1 ratio, to receive diltiazem
      administered parenterally at a dose of 0.25 mg/kg (to a maximum dose of 30 mg) or metoprolol
      administered at a dose of 0.15 mg/kg (to a maximum dose of 10 mg). Randomization was
      performed through the use of a computer-generated randomization list. Pharmacy released the
      study drug in a locked tackle box coded in number sequence to correspond to that of the
      computer-generated randomization list, upon which the pharmacist also prepared the study drug
      in blinded fashion. The study medications were packaged in identical-appearing dispensing
      kits. Patients who were randomly assigned to diltiazem received a bolus injection in a
      syringe that appeared identical to that of metoprolol. Admixture and labeling were performed
      by the pharmacist in the ED and dispensed to the treating nurse for administration. Doses of
      each study medication were adjusted with normal saline to a total of 10 ml in each syringe to
      prevent un-blinding. The time at which the first dose was administered was denoted as time
      zero (baseline). If the primary endpoint was not achieved at time 15 minutes, then a second
      escalation dose was administered. If the patient had been enrolled in the diltiazem group,
      the escalation dose was 0.35 mg/kg (to a maximum dose of 30 mg), and for patients enrolled in
      the metoprolol group, the escalation dose was 0.25 mg/kg (to a maximum dose of 10 mg). As
      with the initial dose, the escalation dose was prepared by the pharmacist and given to the
      treating nurse for patient administration in a blinded fashion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Patients Reaching Target HR&lt;100bpm Within 30 Minutes</measure>
    <time_frame>30 minutes</time_frame>
    <description>Percent of patient who reached a HR&lt;100bpm within 30 minutes from baseline.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Heart Rate and Rhythm Disorders</condition>
  <arm_group>
    <arm_group_label>Metoprolol Study Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients Receiving metoprolol administered at a dose of 0.15 mg/kg (to a maximum dose of 10 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diltiazem Study Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving diltiazem administered parenterally at a dose of 0.25 mg/kg (to a maximum dose of 30 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <arm_group_label>Metoprolol Study Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diltiazem</intervention_name>
    <arm_group_label>Diltiazem Study Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Eligible patients had to have a 12-lead electrocardiogram (ECG) showing atrial fibrillation
        or atrial flutter with a ventricular rate of greater than or equal to 120 beats per minute
        and a systolic blood pressure of greater than or equal to 90 mmHg.

        Exclusion Criteria:

        Patients were excluded if they had any of the following:

          -  a systolic blood pressure &lt;90 mmHg, ventricular rate greater than or equal to 220
             beats per minute,

          -  QRS &gt;0.100 seconds, 2nd or 3rd degree atrioventricular (AV) block,

          -  temperature &gt;38.0 ËšC,

          -  acute ST elevation myocardial infarction,

          -  known history of New York Heart Association Class IV heart failure or

          -  active wheezing with a history of bronchial asthma or COPD.

        In addition, patients were excluded if there was:

          -  prehospital administration of diltiazem or any other AV nodal blockading agent,

          -  a history of cocaine or methamphetamine use in the previous 24 hours prior to arrival,

          -  a history of allergic reaction to diltiazem or metoprolol,

          -  a history of sick sinus or pre-excitation syndromes,

          -  a history of anemia with hemoglobin &lt;11.0 g/dl,

          -  pregnancy or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Marshall, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Maimonides Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Scott PA, Pancioli AM, Davis LA, Frederiksen SM, Eckman J. Prevalence of atrial fibrillation and antithrombotic prophylaxis in emergency department patients. Stroke. 2002 Nov;33(11):2664-9.</citation>
    <PMID>12411658</PMID>
  </reference>
  <reference>
    <citation>McDonald AJ, Pelletier AJ, Ellinor PT, Camargo CA Jr. Increasing US emergency department visit rates and subsequent hospital admissions for atrial fibrillation from 1993 to 2004. Ann Emerg Med. 2008 Jan;51(1):58-65. Epub 2007 Apr 27.</citation>
    <PMID>17466409</PMID>
  </reference>
  <reference>
    <citation>Friberg J, Buch P, Scharling H, Gadsbphioll N, Jensen GB. Rising rates of hospital admissions for atrial fibrillation. Epidemiology. 2003 Nov;14(6):666-72.</citation>
    <PMID>14569181</PMID>
  </reference>
  <reference>
    <citation>Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation. 2003 Aug 12;108(6):711-6. Epub 2003 Jul 28.</citation>
    <PMID>12885749</PMID>
  </reference>
  <reference>
    <citation>Stiell IG, Clement CM, Perry JJ, Vaillancourt C, Symington C, Dickinson G, Birnie D, Green MS. Association of the Ottawa Aggressive Protocol with rapid discharge of emergency department patients with recent-onset atrial fibrillation or flutter. CJEM. 2010 May;12(3):181-91.</citation>
    <PMID>20522282</PMID>
  </reference>
  <reference>
    <citation>Friedman HZ, Goldberg SF, Bonema JD, Cragg DR, Hauser AM. Acute complications associated with new-onset atrial fibrillation. Am J Cardiol. 1991 Feb 15;67(5):437-9.</citation>
    <PMID>1994672</PMID>
  </reference>
  <reference>
    <citation>Chenoweth J, Diercks DB. Management of atrial fibrillation in the acute setting. Curr Opin Crit Care. 2012 Aug;18(4):333-40. doi: 10.1097/MCC.0b013e328354dc30. Review.</citation>
    <PMID>22622515</PMID>
  </reference>
  <reference>
    <citation>Demircan C, Cikriklar HI, Engindeniz Z, Cebicci H, Atar N, Guler V, Unlu EO, Ozdemir B. Comparison of the effectiveness of intravenous diltiazem and metoprolol in the management of rapid ventricular rate in atrial fibrillation. Emerg Med J. 2005 Jun;22(6):411-4. Erratum in: Emerg Med J. 2005 Oct;22(10):758.</citation>
    <PMID>15911947</PMID>
  </reference>
  <reference>
    <citation>Kovacic JC, Moreno P, Nabel EG, Hachinski V, Fuster V. Cellular senescence, vascular disease, and aging: part 2 of a 2-part review: clinical vascular disease in the elderly. Circulation. 2011 May 3;123(17):1900-10. doi: 10.1161/CIRCULATIONAHA.110.009118. Review.</citation>
    <PMID>21537006</PMID>
  </reference>
  <reference>
    <citation>Stiell IG, Macle L; CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: management of recent-onset atrial fibrillation and flutter in the emergency department. Can J Cardiol. 2011 Jan-Feb;27(1):38-46. doi: 10.1016/j.cjca.2010.11.014. Erratum in: Can J Cardiol. 2012 Mar-Apr;28(2):244. Dosage error in article text.</citation>
    <PMID>21329861</PMID>
  </reference>
  <reference>
    <citation>Rogenstein C, Kelly AM, Mason S, Schneider S, Lang E, Clement CM, Stiell IG. An international view of how recent-onset atrial fibrillation is treated in the emergency department. Acad Emerg Med. 2012 Nov;19(11):1255-60. doi: 10.1111/acem.12016.</citation>
    <PMID>23167856</PMID>
  </reference>
  <reference>
    <citation>Maxwell CJ, Hogan DB, Campbell NR, Ebly EM. Nifedipine and mortality risk in the elderly: relevance of drug formulation, dose and duration. Pharmacoepidemiol Drug Saf. 2000 Jan;9(1):11-23. doi: 10.1002/(SICI)1099-1557(200001/02)9:1&lt;11::AID-PDS468&gt;3.0.CO;2-U.</citation>
    <PMID>19025798</PMID>
  </reference>
  <reference>
    <citation>Jollis JG, Simpson RJ Jr, Chowdhury MK, Cascio WE, Crouse JR 3rd, Massing MW, Smith SC Jr. Calcium channel blockers and mortality in elderly patients with myocardial infarction. Arch Intern Med. 1999 Oct 25;159(19):2341-8.</citation>
    <PMID>10547174</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2013</study_first_submitted>
  <study_first_submitted_qc>July 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2013</study_first_posted>
  <results_first_submitted>October 23, 2013</results_first_submitted>
  <results_first_submitted_qc>October 23, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 16, 2013</results_first_posted>
  <last_update_submitted>May 1, 2014</last_update_submitted>
  <last_update_submitted_qc>May 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Maimonides Medical Center</investigator_affiliation>
    <investigator_full_name>Antonios Likourezos</investigator_full_name>
    <investigator_title>Research Manager</investigator_title>
  </responsible_party>
  <keyword>metoprolol</keyword>
  <keyword>diltiazem</keyword>
  <keyword>heart rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Atrial Flutter</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Diltiazem</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment of patients was from June 2009 to November 2010</recruitment_details>
      <pre_assignment_details>No significant events</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Metoprolol Study Group</title>
          <description>Patients Receiving metoprolol administered at a dose of 0.15 mg/kg (to a maximum dose of 10 mg)</description>
        </group>
        <group group_id="P2">
          <title>Diltiazem Study Group</title>
          <description>Patients receiving diltiazem administered parenterally at a dose of 0.25 mg/kg (to a maximum dose of 30 mg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>uncooperative, agitated and removed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metoprolol Study Group</title>
          <description>Patients Receiving metoprolol administered at a dose of 0.15 mg/kg (to a maximum dose of 10 mg)</description>
        </group>
        <group group_id="B2">
          <title>Diltiazem Study Group</title>
          <description>Patients receiving diltiazem administered parenterally at a dose of 0.25 mg/kg (to a maximum dose of 30 mg)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.95" spread="14.94"/>
                    <measurement group_id="B2" value="65.85" spread="13.22"/>
                    <measurement group_id="B3" value="67.52" spread="14.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Patients Reaching Target HR&lt;100bpm Within 30 Minutes</title>
        <description>Percent of patient who reached a HR&lt;100bpm within 30 minutes from baseline.</description>
        <time_frame>30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metoprolol Study Group</title>
            <description>Patients Receiving metoprolol administered at a dose of 0.15 mg/kg (to a maximum dose of 10 mg)</description>
          </group>
          <group group_id="O2">
            <title>Diltiazem Study Group</title>
            <description>Patients receiving diltiazem administered parenterally at a dose of 0.25 mg/kg (to a maximum dose of 30 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients Reaching Target HR&lt;100bpm Within 30 Minutes</title>
          <description>Percent of patient who reached a HR&lt;100bpm within 30 minutes from baseline.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.4"/>
                    <measurement group_id="O2" value="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We estimated a sample size of 200 patients assigned in a 1:1 ratio to receive diltiazem and metoprolol would achieve 80% power to detect non-inferiority using a one-sided two sample t-test. The margin of equivalence is -10.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Chi-Square test</non_inferiority_desc>
            <p_value>.0001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Metoprolol Study Group</title>
          <description>Patients Receiving metoprolol administered at a dose of 0.15 mg/kg (to a maximum dose of 10 mg)</description>
        </group>
        <group group_id="E2">
          <title>Diltiazem Study Group</title>
          <description>Patients receiving diltiazem administered parenterally at a dose of 0.25 mg/kg (to a maximum dose of 30 mg)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christian Fromm, MD; Director of Research</name_or_title>
      <organization>Maimonides Medical Center</organization>
      <phone>718-283-6391</phone>
      <email>cfromm@maimonidesmed.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

